Clinical Trial: SWOG S2007

SWOG S2007

Status: Open

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

S2007 will close to accrual, effective April 7, 2025 at 12:00pm ET.